IN2015KN00329A - - Google Patents

Info

Publication number
IN2015KN00329A
IN2015KN00329A IN329KON2015A IN2015KN00329A IN 2015KN00329 A IN2015KN00329 A IN 2015KN00329A IN 329KON2015 A IN329KON2015 A IN 329KON2015A IN 2015KN00329 A IN2015KN00329 A IN 2015KN00329A
Authority
IN
India
Prior art keywords
compositions
diseases
disclosed
methods
encompass
Prior art date
Application number
Other languages
English (en)
Inventor
Christopher K Garcia
Darren L Bates
Ignacio Moraga
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of IN2015KN00329A publication Critical patent/IN2015KN00329A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN329KON2015 2012-08-09 2013-08-08 IN2015KN00329A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261681490P 2012-08-09 2012-08-09
US201261725791P 2012-11-13 2012-11-13
US201361825980P 2013-05-21 2013-05-21
PCT/US2013/054164 WO2014074186A2 (en) 2012-08-09 2013-08-08 Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Publications (1)

Publication Number Publication Date
IN2015KN00329A true IN2015KN00329A (zh) 2015-07-10

Family

ID=50685291

Family Applications (1)

Application Number Title Priority Date Filing Date
IN329KON2015 IN2015KN00329A (zh) 2012-08-09 2013-08-08

Country Status (6)

Country Link
US (3) US9738696B2 (zh)
EP (1) EP2882449B1 (zh)
JP (2) JP6445434B2 (zh)
CN (2) CN110615835A (zh)
IN (1) IN2015KN00329A (zh)
WO (1) WO2014074186A2 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019003744A (es) * 2016-09-30 2019-10-30 Univ Leland Stanford Junior Interferones de variante tipo iii y sintecinas.
JP2018157812A (ja) * 2017-03-23 2018-10-11 東ソー株式会社 試料中に含まれる細胞の検出方法
US20210260162A1 (en) * 2017-03-31 2021-08-26 The Board Of Trustees Of The Leland Stanford Junior University Synthekine compositions and methods of use
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
JP2021523741A (ja) 2018-05-14 2021-09-09 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン１２ポリペプチド及びその使用方法
WO2019232523A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
WO2020212602A1 (en) 2019-04-19 2020-10-22 Synerkine Pharma B.V. Therapeutic crosslinking of cytokine receptors
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
WO2023230163A1 (en) * 2022-05-24 2023-11-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin 4 and/or interleukin 13-based eye compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US6335426B1 (en) * 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
WO2011106779A1 (en) 2010-02-26 2011-09-01 Aerovance Inc. Use of modified il-4 mutien receptor antagonists to treat dermatitis

Also Published As

Publication number Publication date
CN104619334A (zh) 2015-05-13
EP2882449A2 (en) 2015-06-17
CN110615835A (zh) 2019-12-27
WO2014074186A2 (en) 2014-05-15
JP6445434B2 (ja) 2018-12-26
EP2882449B1 (en) 2019-05-15
US9738696B2 (en) 2017-08-22
US10738096B2 (en) 2020-08-11
US20160244499A1 (en) 2016-08-25
EP2882449A4 (en) 2016-03-09
JP2018161143A (ja) 2018-10-18
WO2014074186A3 (en) 2014-06-19
US20180016316A1 (en) 2018-01-18
US20210188932A1 (en) 2021-06-24
JP2015525574A (ja) 2015-09-07

Similar Documents

Publication Publication Date Title
IN2015KN00329A (zh)
CY1123106T1 (el) Αγωγη ανοσοσχετιζομενων και φλεγμονωδων νοσων
SG10201804330YA (en) Engineered high-affinity human t cell receptors
EP3458485A4 (en) RELATED INTERLEUKIN-2 TO ITS RECEPTOR IL-2RBETA, A PLATFORM FOR INCREASING THE ACTIVITY OF NATURAL KILLER AND REGULATORY T CELLS
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
MX347703B (es) Co-agonistas del receptor de glucagon/glp-1.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
MX2015012933A (es) Micrordenamiento para suministro de agente terapeutico y metodos de uso.
MX363226B (es) Formulaciones de anticuerpos.
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX2015014438A (es) Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
MY156697A (en) Modified tuberculosis antigens
MY181994A (en) Immuno-modulatory progenitor (imp) cell
EP2558124A4 (en) POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION
CR20160576A (es) Anticuerpos dirigidos contra cd127
HK1224333A1 (zh) 具有免疫調節活性的細胞群，其製備方法及其用途
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2015003765A (es) Arterivirus.
WO2013109055A3 (ko) 개 유래의 자연살해세포 및 이의 대량 증식방법
ES2673028T3 (es) Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
MY175743A (en) Combination treatment comprising sulphated glycosaminoglycans for inducing labor